You are here

P&T News

September 30

Device has shelf life of 12 to 18 months
Glecaprevir/pibrentasvir combo achieves high virologic response rates
Pivotal study meets all secondary endpoints

September 29

More than 3,000 cases reported in continental U.S.
Lumacaftor/ivacaftor combination previously approved for patients 12 years of age and older
“Artificial pancreas” adjusts insulin levels
Treatment reduces monthly migraine days

September 28

Singleplex trumps Trioplex, lab chief says
Arm patch provides continuous glucose monitoring
Compound could be used in new anti-inflammatory agents
Approval decision scheduled for July
First stakeholder meeting to be held this month

September 27

Regimen will target five tumor types and have seven indications
Endocrine Society publishes guideline evaluating technologies for treating diabetes
Combination did not improve progression-free survival for newly diagnosed patients
NIH-funded study seeks to explain the group’s disproportionate risk of the disease
Study includes nations that differ in economic development, income, and culture

Pages